Global calcium channel blocker market is expected to reach USD 15.31 billion, growing at a CAGR of 5.4% between 2017 and 2022.

Sarasota, FL -- (SBWire) -- 04/07/2017 --Zion Market Research has published a new report titled "Calcium Channel Blocker Market by Drug class (Dihydropyridine and Non-Dihydropyridine) for Hypertension, Angina Pectoris, Pregnancy, Obesity and Other - Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022". According to the report, the global calcium channel blocker market accounted for USD 11.26 billion in 2016 and is expected to reach USD 15.31 billion, growing at a CAGR of around 5.4% between 2017 and 2022.

Calcium channel blockers are the chemical class of antihypertensive drugs used to treat various ill conditions of the heart and blood vessels. For example, CCB is commonly used in the treatment of angina pectoris, hypertension, and Reynaud's phenomenon. Combination therapy is commonly used in the treatment of high blood pressure or angina pectoris.

Request Free Sample Research Report @ https://www.zionmarketresearch.com/sample/calcium-channel-blocker-market

Based on product, calcium channel blocker market is segmented into two types: Dihydropyridine and Non-Dihydropyridine. Dihydropyridine is one of the important groups of calcium channel blocker which held approximately 65%of the overall market in 2016. Dihydropyridineclass is expected to be the largest segment in the market due to growing demand from pharmaceutical industry.Lower cost and easy availability of the products is expected to propel the growth of Dihydropyridinesegment.Dihydropyridine class of CCB market is further sub-segmented into Amlodipine, Cilnidipine, Felodipine, Verapamil, Diltiazem, Isradipine, Nicardipine, Nisoldipine, Nifedipine, and others.Whereas, the Non-Dihydropyridine market is sub-segmented into Diltiazem and Verapamil.

Based on application, calcium channel blocker market segmented into five types: the calcium hypertension, angina pectoris, pregnancy, anti-obesity and other.Hypertension segment the calcium channel blocker market in 2016. For instance, in hypertensionVerapamil and Amlodipine are increasingly used in the pharmaceutical industry. Amlopdipine is a first line therapy for the treatment obesity, angina pectoris and others.

Based on geography, calcium channel blocker market segmented into five major regions: North America, Europe, Asia Pacific, Latin America and Middle East and Africa.North America accounted for the largest share in the market in terms of consumption.Rising percentage of obese and hypertension patient population in Asia Pacific is expected to prompt the growth of calcium channel blocker market within the forecast period.

Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/calcium-channel-blocker-market

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global calcium channel blocker which include Pfizer Inc., AstraZeneca Plc., bayer healthcare LLC., GlaxoSmithKline Plc., Sanofi S.A., Johnson & Johnson, Abcam, AbMole Bioscience, and Clearsynth.

This report segments the global Calcium channel blocker as follows:

Global Calcium Channel Blocker: Drug Type Segment Analysis

Dihydropyridine
Amlodipine
Cilnidipine
Felodipine
Isradipine
Nicardipine
Nisoldipine
Nifedipine
Others
Non-Dihydropyridine
Diltiazem
Verapamil

Global Calcium Channel Blocker: Application Type Segment Analysis

Hypertension
Angina pectoris
Pregnancy
Anti-obesity
Other

Browse detail report with in-depth TOC @ https://www.zionmarketresearch.com/report/calcium-channel-blocker-market

Global Calcium Channel Blocker: Regional Segment Analysis

North America
U.S.
Europe
Asia Pacific
China
Japan
Latin America
Brazil
Middle East and Africa